Skip to main content
Year archive

NIBEC CO., LTD. — 2024 filings

All 23 regulatory filings released by NIBEC CO., LTD. (138610) in 2024, sourced directly from the official regulator.

23 Filings
2024 Period
2024 filings (23)
Filing Released Lang
주주명부폐쇄기간또는기준일설정
Regulatory Filings
2024-12-16 Korean
전환가액의조정
Share Issue/Capital Change
2024-11-22 Korean
분기보고서 (2024.09)
Interim / Quarterly Report 9M 2024
2024-11-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (나이벡 펩타이드 기반 염증성장질환치료제(NIPEP-IBD, 코드명 NP-201) 호주 임상 1b/2a 임상 시험계획 승인)
Legal Proceedings Report
2024-11-11 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (나이벡 펩타이드 기반 NP201 호주 임상 1b/2a 임상 시험계획 신청)
Regulatory Filings
2024-10-22 Korean
전환청구권행사
Share Issue/Capital Change
2024-10-17 Korean
전환청구권행사
Share Issue/Capital Change
2024-10-16 Korean
투자판단관련주요경영사항 (중국시장 독점판매권 회수 및 보상금 지급의 건)
M&A Activity
2024-09-11 Korean
반기보고서 (2024.06)
Interim / Quarterly Report H1 2024
2024-08-13 Korean
전환가액의조정
Share Issue/Capital Change
2024-05-22 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Q1 2024
2024-05-13 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements
2024-03-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information
2024-03-29 Korean
감사보고서제출
Audit Report / Information FY 2023
2024-03-21 Korean
사업보고서 (2023.12)
Annual Report FY 2023
2024-03-21 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement
2024-03-12 Korean
주주총회소집공고
AGM Information
2024-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release FY 2023
2024-03-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement
2024-03-12 Korean
주주총회집중일개최사유신고
AGM Information
2024-03-12 Korean
[기재정정]사업보고서 (2022.12)
Annual Report FY 2022
2024-03-11 Korean
[기재정정]파생상품거래손실발생
Earnings Release FY 2022
2024-03-11 Korean
[기재정정]감사보고서제출
Audit Report / Information FY 2023
2024-03-11 Korean